FSH as a biomarker of bone strength in younger postmenopausal women

描述（由申请人提供）： NIH Consensus Panel 2000将骨质疏松症描述为一种骨骼疾病，其特征是骨强度受损，易导致骨折风险增加。本研究的长期目的是了解血清促卵泡激素（FSH）是否可在临床上用作生物标志物，以识别骨强度两个可测量组分显著下降的年轻绝经后女性：面积骨矿物质密度（通过双能X线吸收测定法测量）和骨质量（通过外周定量计算机断层扫描[pQCT]评估）。FSH相关变量和低骨密度之间的关联已在动物模型和绝经前和围绝经期妇女的队列研究中报告;然而，迄今为止还没有研究测试FSH和骨质之间可能的关系。在对16名年龄在50 ~ 64岁的绝经后妇女的研究中，我们发现乘法变量FSH-年和桡骨远端的面积骨密度之间存在中度和统计学显著的未校正相关性。在拟议的项目中，我们还将测试FSH相关变量和前臂远端骨质的pQCT测量值之间的相关性，解释激素对骨骼的影响。具体目标：1）在一项横断面研究中，对111名年龄在50至64岁之间的绝经后妇女进行了调查，从初级保健诊所招募，评估血清FSH与以下因素之间的关系：a）骨质量，B）骨密度，c）骨转换; 2）测试FSH是否与桡骨远端的骨质量和骨密度独立相关，调整其他激素因素。自2005年2月以来，我们的多学科研究团队在北卡罗来纳州大学NIH资助的一般临床研究中心进行了一项骨相关生物标志物研究。我们将扩展本研究，以纳入新的激素测量和针对拟议项目的骨pQCT成像的专门分析。结果将显示未来的研究是否应该测试FSH的诊断准确性，以确定高风险的年轻绝经后妇女谁可以受益于预防性干预措施之前，推荐的年龄进行常规骨质疏松症筛查。骨质疏松症是一种骨强度低的疾病，导致老年妇女的高骨相关发病率和死亡率。本研究将探讨血清FSH作为年轻绝经后妇女骨强度低的临床生物标志物的可能性。

DESCRIPTION (provided by applicant): The NIH Consensus Panel 2000 described osteoporosis as a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture. The long-term objective of the proposed study is to learn whether serum follicle stimulating hormone (FSH) could be used clinically as a biomarker to identify younger postmenopausal women with significant declines in the two measurable components of bone strength: areal bone mineral density (measured by dual-energy x-ray absorptiometry) and bone quality (assessed by peripheral quantitative computed tomography [pQCT]). Associations between FSH-related variables and low bone density have been reported in animal models and a cohort study of pre- and perimenopausal women; however, no study to date has tested for a possible relationship between FSH and bone quality. In a study of 16 postmenopausal women aged 50 to 64 years, we found a moderate and statistically significant unadjusted correlation between the multiplicative variable FSH-years and areal bone density in the distal radius. In the proposed project, we will also test for correlations between FSH-related variables and pQCT measures of bone quality in the distal forearm, accounting for hormonal influences on bone. Specific Aims: 1) In a cross-sectional study of 111 postmenopausal women aged 50 to 64 years recruited from primary care clinics, evaluate the relationship between serum FSH and: a) bone quality, b) bone mineral density, c) bone turnover; 2) Test whether FSH is independently associated with bone quality and bone mineral density in the distal radius, adjusted for other hormonal factors. Our multidisciplinary research team has conducted a study of bone- related biomarkers in the NIH-funded General Clinical Research Center at the University of North Carolina since February 2005. We will extend this study to include new hormonal measures and specialized analysis of pQCT imaging of bone for the proposed project. Results will show whether future studies should test the diagnostic accuracy of FSH to identify high-risk younger postmenopausal women who could benefit from preventive interventions before the recommended age for routine osteoporosis screening. PROJECT NARRATIVE Osteoporosis is a condition of low bone strength that leads to high fracture-related morbidity and mortality in elderly women. This study will examine the potential for serum FSH to be used clinically as a biomarker of low bone strength in younger postmenopausal women.